INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Greenstreet Yvonne sold ALNY

Director, Chief Executive Officer · ALNYLAM PHARMACEUTICALS, INC. · Common Stock

Side
SELL
Value
$485K
Shares
1,069
Price
$453.52
Executed
Nov 12, 2025
Disclosed
Nov 14, 2025
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Nov 12 executedNov 14, 2025 disclosed

ALNY · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
11/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+7 / 25

    $485K reported value · 1.4% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ALNY

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    23
    FJ
    Fitzgerald Kevin JosephCSO & EVP, Head of Research
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$80K
    220 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    20
    FJ
    Fitzgerald Kevin JosephCSO & EVP, Head of Research
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$34K
    92 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    20
    FJ
    Fitzgerald Kevin JosephCSO & EVP, Head of Research
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$26K
    73 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    23
    FJ
    Fitzgerald Kevin JosephCSO & EVP, Head of Research
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$73K
    199 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    20
    FJ
    Fitzgerald Kevin JosephCSO & EVP, Head of Research
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$18K
    50 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    20
    FJ
    Fitzgerald Kevin JosephCSO & EVP, Head of Research
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$15K
    41 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    32
    GY
    Greenstreet YvonneDirector, Chief Executive Officer
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$168K
    464 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    20
    FJ
    Fitzgerald Kevin JosephCSO & EVP, Head of Research
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$35K
    98 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    36
    GP
    Garg PushkalEVP Chief R&D
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$7,137
    19 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    20
    FJ
    Fitzgerald Kevin JosephCSO & EVP, Head of Research
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$17K
    47 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    39
    PV
    Poulton Jeffrey V.EVP, Chief Financial Officer
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$133K
    365 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    23
    FJ
    Fitzgerald Kevin JosephCSO & EVP, Head of Research
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$56K
    155 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    20
    FJ
    Fitzgerald Kevin JosephCSO & EVP, Head of Research
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$14K
    39 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    9
    FJ
    Fitzgerald Kevin JosephCSO & EVP, Head of Research
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Grant or award · 10b5-1 plan
    		A—
    3,800 sh
    		Jan 11, 2026Jan 14, 2026
    traded Jan 11, 2026
    		+3dSEC FORM 4

    Evidence

    36
    TT
    Tanguler TolgaEVP, Chief Commercial Officer
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$745
    2 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    39
    GP
    Garg PushkalEVP Chief R&D
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$56K
    155 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    36
    GP
    Garg PushkalEVP Chief R&D
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$31K
    85 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    36
    TT
    Tanguler TolgaEVP, Chief Commercial Officer
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$5,242
    14 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    39
    GP
    Garg PushkalEVP Chief R&D
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$80K
    220 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    36
    GP
    Garg PushkalEVP Chief R&D
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$35K
    98 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001735276-25-000120
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Nov 12, 2025
    Published
    Nov 14, 2025
    Ingested by INSIDER
    Nov 5, 04:33 UTC
    Last re-read
    Nov 5, 04:33 UTC

    Extracted facts

    Filer
    Greenstreet Yvonne
    Role
    Director, Chief Executive Officer
    Transaction
    Open-market saleAs filed: “S”
    Asset
    ALNYLAM PHARMACEUTICALS, INC.
    Ticker
    ALNY
    Shares
    1,069
    Price per share
    $453.52
    Value
    $484,813
    Execution date (reported)
    Nov 12, 2025
    Owned after transaction
    74.2K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 1,069
    • Price: $453.52

    = $484,813

    What this establishes

    Greenstreet Yvonne filed this Form 4 reporting a open-market sale of ALNY on Nov 12, 2025. It became public on Nov 14, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, Chief Executive Officer
    Greenstreet Yvonnecik:0001446125
    Issuer
    ALNYLAM PHARMACEUTICALS, INC.cik:0001178670

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.

    Data sources
    SEC FORM 46m ago
    HOUSE PTR6m ago
    SEC 13F6m ago
    ROBINHOOD CHAIN6m ago